These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 18279417

  • 1. Obesity following kidney transplantation and steroid avoidance immunosuppression.
    Elster EA, Leeser DB, Morrissette C, Pepek JM, Quiko A, Hale DA, Chamberlain C, Salaita C, Kirk AD, Mannon RB.
    Clin Transplant; 2008; 22(3):354-9. PubMed ID: 18279417
    [Abstract] [Full Text] [Related]

  • 2. Excellent clinical outcomes in primary kidney transplant recipients treated with steroid-free maintenance immunosuppression.
    Rajab A, Pelletier RP, Henry ML, Ferguson RM.
    Clin Transplant; 2006; 20(5):537-46. PubMed ID: 16968478
    [Abstract] [Full Text] [Related]

  • 3. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
    Jaber JJ, Feustel PJ, Elbahloul O, Conti AD, Gallichio MH, Conti DJ.
    Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
    [Abstract] [Full Text] [Related]

  • 4. Early discontinuation of steroids is safe and effective in pediatric kidney transplant recipients.
    Oberholzer J, John E, Lumpaopong A, Testa G, Sankary HN, Briars L, Kraft KA, Knight PS, Verghese P, Benedetti E.
    Pediatr Transplant; 2005 Aug; 9(4):456-63. PubMed ID: 16048597
    [Abstract] [Full Text] [Related]

  • 5. Results of one-year follow-up of steroid-free immunosuppression in pediatric renal transplant patients.
    Silverstein DM, Aviles DH, LeBlanc PM, Jung FF, Vehaskari VM.
    Pediatr Transplant; 2005 Oct; 9(5):589-97. PubMed ID: 16176415
    [Abstract] [Full Text] [Related]

  • 6. Steroid-avoidance immunosuppression regimen in live-donor renal allotransplant recipients: a prospective, randomized, controlled study.
    Nematalla AH, Bakr MA, Gheith OA, Elagroudy AE, Elshahawy el-M, Aghoneim M.
    Exp Clin Transplant; 2007 Dec; 5(2):673-9. PubMed ID: 18194120
    [Abstract] [Full Text] [Related]

  • 7. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
    Kato Y, Tojimbara T, Iwadoh K, Koyama I, Nanmoku K, Kai K, Sannomiya A, Nakajima I, Fuchinoue S, Teraoka S.
    Int Immunopharmacol; 2006 Dec 20; 6(13-14):1984-92. PubMed ID: 17161352
    [Abstract] [Full Text] [Related]

  • 8. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B, Höcker B.
    Pediatr Transplant; 2006 Sep 20; 10(6):721-9. PubMed ID: 16911497
    [Abstract] [Full Text] [Related]

  • 9. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation.
    Sarwal MM, Vidhun JR, Alexander SR, Satterwhite T, Millan M, Salvatierra O.
    Transplantation; 2003 Nov 15; 76(9):1331-9. PubMed ID: 14627912
    [Abstract] [Full Text] [Related]

  • 10. Can pediatric steroid-free renal transplantation improve growth and metabolic complications?
    Bhakta N, Marik J, Malekzadeh M, Gjertson D, Ettenger R.
    Pediatr Transplant; 2008 Dec 15; 12(8):854-61. PubMed ID: 18482211
    [Abstract] [Full Text] [Related]

  • 11. Sirolimus induced dyslipidemia in tacrolimus based vs. tacrolimus free immunosuppressive regimens in renal transplant recipients.
    Hakeam HA, Al-Jedai AH, Raza SM, Hamawi K.
    Ann Transplant; 2008 Dec 15; 13(2):46-53. PubMed ID: 18566560
    [Abstract] [Full Text] [Related]

  • 12. Development of growth and body mass index after pediatric renal transplantation.
    Vester U, Schaefer A, Kranz B, Wingen AM, Nadalin S, Paul A, Malagò M, Broelsch CE, Hoyer PF.
    Pediatr Transplant; 2005 Aug 15; 9(4):445-9. PubMed ID: 16048595
    [Abstract] [Full Text] [Related]

  • 13. One-year results of basiliximab induction and tacrolimus associated with sequential steroid and MMF treatment in pediatric kidney transplant recipient.
    Montini G, Murer L, Ghio L, Pietrobon B, Ginevri F, Ferraresso M, Cardillo M, Scalamogna M, Perfumo F, Edefonti A, Zanon GF, Zacchello G.
    Transpl Int; 2005 Jan 15; 18(1):36-42. PubMed ID: 15612981
    [Abstract] [Full Text] [Related]

  • 14. Improved cardiovascular risk factors in pediatric renal transplant recipients on steroid avoidance immunosuppression: A study of the Midwest Pediatric Nephrology Consortium.
    Weaver DJ, Selewski D, Janjua H, Iorember F.
    Pediatr Transplant; 2016 Feb 15; 20(1):59-67. PubMed ID: 26585354
    [Abstract] [Full Text] [Related]

  • 15. Trends in adult post-kidney transplant immunosuppressive use in Australia, 1991-2005.
    Chang SH, Russ GR, Chadban SJ, Campbell S, McDonald SP.
    Nephrology (Carlton); 2008 Apr 15; 13(2):171-6. PubMed ID: 18275507
    [Abstract] [Full Text] [Related]

  • 16. Randomized trial of dual antibody induction therapy with steroid avoidance in renal transplantation.
    Ciancio G, Gaynor JJ, Sageshima J, Guerra G, Zarak A, Roth D, Brown R, Kupin W, Chen L, Hanson L, Tueros L, Ruiz P, Livingstone AS, Burke GW.
    Transplantation; 2011 Dec 27; 92(12):1348-57. PubMed ID: 22027927
    [Abstract] [Full Text] [Related]

  • 17. Prednisone withdrawal in pediatric kidney transplant recipients on tacrolimus-based immunosuppression: four-year data.
    Hamiwka LA, Burns A, Bell L.
    Pediatr Transplant; 2006 May 27; 10(3):337-44. PubMed ID: 16677358
    [Abstract] [Full Text] [Related]

  • 18. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen.
    Yang SL, Wang D, Wu WZ, Lin WH, Xu TZ, Cai JQ, Tan JM.
    Transpl Immunol; 2008 Jan 27; 18(3):281-5. PubMed ID: 18047938
    [Abstract] [Full Text] [Related]

  • 19. Steroid avoidance immunosuppression in low-risk kidney transplant recipients.
    Heilman RL, Mazur MJ, Reddy KS, Moss A, Post D, Mulligan D.
    Transplant Proc; 2005 May 27; 37(4):1785-8. PubMed ID: 15919466
    [Abstract] [Full Text] [Related]

  • 20. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage.
    Liu CL, Fan ST, Lo CM, Chan SC, Ng IO, Lai CL, Wong J.
    Liver Transpl; 2004 Jun 27; 10(6):728-33. PubMed ID: 15162466
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.